News Release

Journal Article Cites HemoVoid™ in Biomarker Quantification for LC-MS Proteomic Analysis of Erythrocytes in Parkinson’s Disease

MONMOUTH JUNCTION, NJ, February 13, 2020 -- Biotech Support Group reports on a recent research article describing the simplicity and efficiency of their hemoglobin depletion technology for enriching the red cell low abundance proteome, to quantify abundance changes in red cells that might occur in Parkinson’s Disease.

The citation is:

Klatt, Stephan, et al. "Optimizing red blood cell protein extraction for biomarker quantitation with mass spectrometry." Analytical and Bioanalytical Chemistry (2020): 1-14.

Red blood cells (RBCs) might serve as a reservoir for biomarker research as they are anuclear and lack the ability to synthesize proteins. Yet few biomarker assays have been conducted on RBCs because of their large dynamic range of proteins, high abundance of lipids, and the large amount of hemoglobin interference. In this study, the author’s developed a semiquantitative mass spectrometry–based assay that targeted 144 proteins and compared the efficiency of urea, sodium deoxycholate, acetonitrile, and HemoVoid™ as a sample prep step for the RBC proteome. The article describes the advantage of HemoVoid™ in detection of low abundance proteins when comparing their amounts (in percent) between with the other four extraction conditions. With respect to Parkinson’s Disease, the article states “For example, PRDX6 accounts for 0.4% of the total ion abundance after DOC (deoxycholate) extraction, whereas following HV (HemoVoid™) extraction, this increases to 8%, a 20-fold enrichment”. The authors conclude that the HemoVoid™ method significantly reduces the concentration of hemoglobin, resulting in an increased signal-to noise of the remaining proteins. This is especially useful for low abundance proteins and for those which might be close to the limit of detection without depletion. 

“Here is another HemoVoid™ report demonstrating a very important advantage, that through a negative selection strategy, you can deplete Hemoglobin as it very selectively passes through the beads without binding. By that process, you can achieve enrichment of the underlying red cell proteome which can then be on-bead digested, greatly simplifying the workflow. This we hope will lead to new biomarkers for many diseases like Parkinson’s”, states Swapan Roy, Ph.D., President and Founder of Biotech Support Group. 

For more information on HemoVoid™, visit:

http://www.biotechsupportgroup.com/HemoVoid-Hemoglobin-Depletion-From-Erythrocytes-p/hvk.htm

For more information of all of our Hemoglobin removal products, visit:

https://www.biotechsupportgroup.com/Articles.asp?ID=452

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

Contact:
Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com